Adverum Biotechnologies Reports Second Quarter 2019 Financial Results and Provides Corporate Update
-- Phase 1 OPTIC trial: 24-week data from first cohort to be presented at
-- Dosing of second cohort completed; 24-week data to be presented in 1H20 --
-- IND submission for ADVM-022 in diabetic retinopathy planned in 1H20 --
-- Company to host conference call today at
“We are extremely pleased with the clinical and regulatory progress made with our lead clinical candidate, ADVM-022, including acceptance of OPTIC data in wet AMD for oral presentation at the
Recent Program Updates and Future Outlook
- Adverum will report 24-week primary and secondary outcomes from the first cohort of patients (n=6; dose of 6x10^11 vg/eye) in the Phase 1 OPTIC trial during a podium presentation at the
Retina SocietyAnnual Meeting on September 12, 2019. 52-week data are expected to be presented in the first half of 2020.
- Dosing of the second cohort of patients (n=6; lower dose of 2x10^11 vg/eye) was recently completed, and 24-week data are expected to be presented in the first half of 2020. The company will provide an update on further plans for the OPTIC trial in the fourth quarter of 2019.
- Adverum plans to advance ADVM-022 into the clinic for the treatment of patients with diabetic retinopathy (DR), a key VEGF-driven cause of vision loss among working-age adults, and intends to submit an IND in the first half of 2020.
- For the company’s rare disease programs, Adverum has discontinued development of its gene therapy program targeting A1AT deficiency (ADVM-043) and has moved its gene therapy program targeting hereditary angioedema (ADVM-053) back into early development.
Recent Corporate Updates and Future Outlook
August 2019, Adverum announced that board member and co-founder Mitchell Finer, Ph.D. retired from the Board of Directors to focus on a new industry role.
Mehdi Gasmi, Ph.D. will retire from his position as president and chief scientific officer of Adverum, effective September 16, 2019, and will join Adverum’s Board of Directors at that time.
- As Adverum builds a team of senior professionals with deep functional expertise to support future growth, the company recently announced the appointments of several vice presidents:
Angela Thedinga, MBA, MPH as vice president, program management and strategy; Dena Houseas vice president, human resources; Myesha Lacyas vice president, investor relations and corporate communications; Carol Hoang, Pharm.D, MBA as vice president, medical affairs; and James Shahbazianas vice president, finance.
June 2019, Adverumand Cornell Universityreached a settlement regarding a Master Service Agreement (MSA) under which Cornellprovided assistance in regulatory affairs, project management, and parameter development. Adverum has made a settlement payment to Cornellof $2.0 million. There was no current period expense from the settlement, as the estimated costs associated with the termination of the MSA were previously accrued during the year ended December 31, 2017. Adverum recognizes Cornell’s time, effort, and professionalism in working through this process.
- Adverum is focused on scaling up its manufacturing process to support the product requirements for later-stage development and commercial use. Its new corporate headquarters in
Redwood Citywill allow for the expansion of in-house process development capabilities to the 1000-liter scale. Adverum expects to be able to occupy its new facility by the end of this year.
Financial Results for the Three Months Ended
- Cash, cash equivalents and short-term investments were
$177.6 millionas of June 30, 2019, compared to $205.1 millionas of December 31, 2018. Adverum expects this quarter-end cash position to fund operations into 2021.
- There was no revenue for the three months ended
June 30, 2019, compared to $0.5 millionfor the same period in 2018. Revenue, consisting of revenue from collaborative research, decreased as no research activities were performed under collaboration agreements for the three-month period in 2019.
- Research and development expenses were
$9.0 millionfor the three months ended June 30, 2019, compared to $11.2 millionfor the same period in 2018. Research and development expenses decreased primarily due to reduced activities related to the development of product candidates ADVM-043 and ADVM-053, partially offset by an increase in facilities cost related to the company’s new facility.
- General and administrative expenses were
$7.1 millionfor the three months ended June 30, 2019, compared to $9.2 millionfor the same period in 2018. General and administrative expenses decreased primarily due to higher severance expenses in the prior period, partially offset by higher spend on consulting, professional services, and facility costs related to the company’s new facility in the current period.
- Net loss attributable to common stockholders was
$15.0 million, or $0.23per basic and diluted share, for the three months ended June 30, 2019, compared to $18.8 million, or $0.30per basic and diluted share, for the same period in 2018.
Conference Call Information
Individuals can participate in today’s conference call at
Adverum is a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases. Adverum develops gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum’s core capabilities include clinical development, novel vector discovery and in-house manufacturing expertise, specifically in scalable process development, assay development, and current Good Manufacturing Practices quality control. For more information, please visit www.adverum.com.
Statements contained in this press release regarding events or results that may occur in the future are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to statements regarding: Adverum’s plans for advancing ADVM-022; the expected timing of reporting clinical data; the expected timing of filing an IND for diabetic retinopathy; expected timing of occupying Adverum’s new facility; and Adverum’s expectations that its current cash position will fund its operations into 2021, all of which are based on certain assumptions made by Adverum on current conditions, expected future developments and other factors Adverum believes are appropriate in the circumstances. Adverum may not achieve any of these a timely manner, or at all, or otherwise carry out the intentions or meet the expectations disclosed in its forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation: risks inherent with conducting clinical trials which may delay or cancel the reporting of data or filing an IND; the incurrence of unexpected expenses; and the risk of a delay in the enrollment of patients in Adverum’s clinical studies or in the manufacturing of products to be used in such clinical studies. Risks and uncertainties facing Adverum are described more fully in Adverum’s Form 10-Q filed with the
|ADVERUM BIOTECHNOLOGIES, INC.|
|CONDENSED CONSOLIDATED BALANCE SHEETS|
|June 30,||December 31,|
|Cash and cash equivalents||$||97,808||$||154,949|
|Prepaid expenses and other current assets||2,919||3,675|
|Total current assets||180,561||208,754|
|Operating lease right-of-use asset||22,053||—|
|Property and equipment, net||6,097||3,586|
|Deposits and other long-term assets||174||156|
|LIABILITIES AND STOCKHOLDERS' EQUITY|
|Accrued expenses and other current liabilities||5,467||8,784|
|Lease liability, current portion||3,942||—|
|Deferred rent, current portion||—||228|
|Total current liabilities||10,149||10,719|
|Deferred rent, less current portion||—||1,366|
|Lease liability, less current portion||21,804||—|
|Other non-current liabilities||191||243|
|Total liabilities and stockholders’ equity||$||209,884||$||213,495|
|ADVERUM BIOTECHNOLOGIES, INC.|
|CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS|
|(In thousands, except per share amounts)|
|Three Months Ended June 30,||Six Months Ended June 30,|
|Collaboration and license revenue||$||—||$||493||$||—||$||709|
|Research and development||8,970||11,217||19,101||24,011|
|General and administrative||7,132||9,179||12,708||14,547|
|Total operating expenses||16,102||20,396||31,809||38,558|
|Other income (expense), net||1,148||1,093||2,366||1,839|
|Net loss per share, basic and diluted||$||(0.23||)||$||(0.30||)||$||(0.46||)||$||(0.60||)|
|Weighted-average common shares outstanding,|
|basic and diluted||63,740||62,366||63,429||59,907|
Investor and Media Inquiries: Investors:
Myesha LacyInvestor Relations and Corporate Communications email@example.com 650-304-3892 Lee M. Stern, CFA Solebury Trout firstname.lastname@example.org 646-378-2922 Media: Joshua R. MansbachSolebury Trout email@example.com 646-378-2964
Source: Adverum Biotechnologies, Inc.